March 28th 2023
Patients with resistant or refractory ovarian cancer experience clinical benefits after receiving botensilimab plus balstilimab in the phase 1 C-800 study.
Leukemia Therapy – A Look Into the Future
View More
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
View More
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
View More
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Community Practice Connections™: 4th annual Precision Medicine Symposium: An Illustrated Tumor Board
View More
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
View More
41st Annual Miami Breast Cancer Conference®
View More
From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis
View More
Medical Crossfire®: How Does the Evidence Inform Your RCC Sequence? The Experts Share Clinical Perspectives
View More
Oncology On-Call®: The Experts’ Take on How Sea Changes in GvHD Prophylaxis and Management Can Be Practically Implemented in Your Clinic
View More
Oncology On-Call®: The Experts’ Take on How Sea Changes in GvHD Prophylaxis and Management Can Be Practically Implemented in Your Clinic
View More
Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Community Practice Connections™: MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
Community Practice Connections™: State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in GvHD Prevention and Treatment
View More
Clinical Vignettes: Inaugural International Congress on Pediatric Oncology
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
Community Practice Connections™: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
View More
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
10/13/2023-10/14/2023
View More
Keeping Pace with Rapid Advancements in Multiple Myeloma Care
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
22nd Annual International Congress on the Future of Breast Cancer® West
07/28/2023 - 07/29/2023
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Oncology Consultations®: Determining Treatment-Related Adverse Events from Disease Progression Along the MPN Care Continuum
View More
Trekking Through the Latest Updates for ROS1-Targeted Therapies
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
View More
Phase 3 IMagyn050 Study Does Not Meet Primary Endpoint of PFS
July 13th 2020The study showed that the addition of atezolizumab to bevacizumab, paclitaxel, and carboplatin as a front-line treatment in women with newly diagnosed advanced stage ovarian cancer did not meet its primary endpoint of progression-free survival.
Karen H. Lu, MD, on Genetic Testing From Patients’ Living Rooms
July 6th 2020At the 2020 ASCO Virtual Scientific Program, Karen H. Lu, MD, presented on findings from the MAGENTA trial, designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.
Phase 3 SOLO2/ENGOT-ov21 Trial Shows Promise for Maintenance Olaparib in Ovarian Cancer
June 29th 2020The results of the trial demonstrated that maintenance olaparib provided an unprecedented improvement in median OS versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Further Anaylses Highlight Benefits of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer
May 13th 2020Multiple abstracts released via the virtual platform for the Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women’s Cancer show mounting evidence for PARP inhibitors as the standard of care in the frontline setting for patients with ovarian cancer.
FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab
May 8th 2020The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
FDA Approves Niraparib for Advanced Ovarian Cancer
April 29th 2020The FDA approved niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.